文献速递认知障碍与痴呆

β-淀粉样蛋白与载脂蛋白E ε4对临床前阿尔茨海默病记忆下降的关联

Association of β-Amyloid and Apolipoprotein E ε4 With Memory Decline in Preclinical Alzheimer Disease.
PubMed 文献 · JAMA Neurol · 2018-01-01

该纵向观察研究纳入447名认知健康老年人,随访72个月,发现Aβ阳性ε4携带者记忆下降从64.5岁开始显著偏离Aβ阴性非携带者,早于Aβ阳性非携带者的76.5岁;到85岁时,其情景记忆复合评分分别差约1.5和0.8个标准差。

要点

  • Aβ阳性ε4携带者记忆下降起始年龄为64.5岁,早于Aβ阳性非携带者的76.5岁。
  • 85岁时Aβ阳性ε4携带者记忆评分较Aβ阴性非携带者差约1.5个标准差。
  • Aβ阴性ε4携带者与Aβ阴性非携带者的记忆表现无显著差异。

核心结论

  • 在认知健康老年人中,Aβ与ε4联合影响记忆下降,且年龄增长可能进一步加剧这种效应。

研究设计与样本

  • 纵向观察研究,纳入澳大利亚AIBL研究中年龄>60岁的认知健康老年人447名,随访超过72个月,每18个月评估一次。

主要发现

  • Aβ阳性ε4携带者记忆下降从64.5岁开始显著偏离Aβ阴性非携带者,而Aβ阳性非携带者从76.5岁开始偏离。
  • 到85岁时,Aβ阳性ε4携带者情景记忆复合评分较Aβ阴性非携带者差约1.5个标准差,较Aβ阳性非携带者差约0.8个标准差。
  • Aβ阴性ε4携带者与Aβ阴性非携带者的记忆表现无显著差异(估计值[SE] 0.001[0.001];t=0.526;P=.77)。

关键数值与推荐

  • Aβ阳性ε4携带者记忆下降起始年龄64.5岁,Aβ阳性非携带者76.5岁。
  • 85岁时Aβ阳性ε4携带者记忆评分较Aβ阴性非携带者差约1.5个标准差,较Aβ阳性非携带者差约0.8个标准差。
  • Aβ阴性ε4携带者与Aβ阴性非携带者记忆评分差异估计值0.001(SE 0.001),t=0.526,P=.77。

临床怎么用

  • 对于Aβ阳性ε4携带的认知健康老年人,可从64.5岁起加强情景记忆监测。
  • Aβ阴性ε4携带者的记忆下降风险与Aβ阴性非携带者相似,可常规随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Older age, high levels of β-amyloid (Aβ), and the presence of the apolipoprotein E (APOE) ε4 allele are risk factors for Alzheimer disease (AD). However, the extent to which increasing age, Aβ, and ε4 are associated with memory decline remains unclear, and the age at which memory decline begins for Aβ-positive ε4 carriers and noncarriers has not been determined. OBJECTIVE: To determine the association of age, Aβ level, and APOE ε4 with memory decline in a large group of cognitively healthy older adults. DESIGN, SETTING, AND PARTICIPANTS: This longitudinal observational study included cognitively healthy older adults (age >60 years) enrolled in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study from March 31, 2006, through March 31, 2017; of 1583 individuals enrolled, 1136 refused or were excluded owing to other criteria (eg, having mild cognitive impairment or AD). Participants underwent Aβ imaging in research clinics in Perth and Melbourne and more than 72 months of follow-up (at 18-month intervals). The association of age with memory was fitted to a quadratic model. Age was treated as a continuous, time-dependent variable. EXPOSURES: β-Amyloid imaging using positron emission tomography, genotyping for APOE ɛ4, and longitudinal neuropsychological assessments of episodic memory during the 72-month follow-up. MAIN OUTCOMES AND MEASURES: Episodic memory composite score. RESULTS: Of the 447 participants, 203 (45.4%) were men and 244 (54.6%) were women; mean (SD) age was 72.5 (6.6) years. Equal proportions of female participants were observed in each Aβ-ɛ4 group (24 of 51 Aβ-positive ε4 noncarriers [47.1%] ; 35 of 64 Aβ-negative ε4 carriers [54.7%]; 40 of 72 Aβ-positive ε4 carriers [55.6%]; and 145 of 260 Aβ-negative ε4 noncarriers [55.8%]). Adults with Aβ findings (mean [SD] age, 74.4 [6.8] years) were approximately 4 years older than those negative for Aβ (mean [SD] age, 69.8 [6.1] years). Memory decline diverged significantly from Aβ-negative ɛ4 noncarriers at an earlier age in Aβ-positive ɛ4 carriers (64.5 years) than in Aβ-positive ɛ4 noncarriers (76.5 years), such that by 85 years of age, Aβ-positive ε4 carriers performed approximately 1.5 SD units worse on the episodic memory composite than Aβ-negative ε4 noncarriers and approximately 0.8 SD units worse than Aβ-positive ε4 noncarriers. Memory performance of Aβ-negative ɛ4 carriers did not differ from that of the Aβ-negative ɛ4 noncarriers (estimate [SE], 0.001 [0.001]; t = 0.526; P = .77). CONCLUSIONS AND RELEVANCE: Prior work has shown that Aβ and ε4 combine to influence memory decline in nondemented older adults. Results of this study indicate that increasing age may further exacerbate these effects. The estimates provided may be used to determine the risk of memory decline associated with Aβ and ε4 at each age.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Lim YY, Kalinowski P, Pietrzak RH, et al. Association of β-Amyloid and Apolipoprotein E ε4 With Memory Decline in Preclinical Alzheimer Disease. JAMA Neurol. 2018. PMID: 29356823. doi:10.1001/jamaneurol.2017.4325

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。